BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Leung WK, Ng SC, Chow DK, Lao WC, Leung VK, Li MK, Hui YT, Ng SS, Hui AJ, Lai ST. Use of biologics for inflammatory bowel disease in Hong Kong: consensus statement. Hong Kong Med J. 2013;19:61-68. [PMID: 23090001 DOI: 10.1007/s00535-012-0673-1] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 8.2] [Reference Citation Analysis]
Number Citing Articles
1 Hisabe T, Hirai F, Matsui T, Watanabe M. Evaluation of diagnostic criteria for Crohn's disease in Japan. J Gastroenterol 2014;49:93-9. [PMID: 23546557 DOI: 10.1007/s00535-013-0798-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
2 Kim ES, Chen M, Lee J, Lee CK, Kim YS. Diagnosis of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization for Crohn's and Colitis (AOCC) meeting in Seoul. Intest Res 2016;14:224-30. [PMID: 27433144 DOI: 10.5217/ir.2016.14.3.224] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
3 Sato R, Nagai H, Matsui H, Yamane A, Kawashima M, Higa K, Nakamura S, Ohshima N, Tamura A, Hebisawa A. Ten Cases of Intestinal Tuberculosis Which Were Initially Misdiagnosed as Inflammatory Bowel Disease. Intern Med 2019;58:2003-8. [PMID: 30918188 DOI: 10.2169/internalmedicine.2361-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Murakami Y, Nishiwaki Y, Oba MS, Asakura K, Ohfuji S, Fukushima W, Suzuki Y, Nakamura Y. Estimated prevalence of ulcerative colitis and Crohn's disease in Japan in 2014: an analysis of a nationwide survey. J Gastroenterol 2019;54:1070-7. [PMID: 31309327 DOI: 10.1007/s00535-019-01603-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
5 Kusaka J, Shiga H, Kuroha M, Kimura T, Kakuta Y, Endo K, Kinouchi Y, Shimosegawa T. Residual Lesions on Capsule Endoscopy Is Associated with Postoperative Clinical Recurrence in Patients with Crohn's Disease. Dig Dis Sci. 2018;63:768-774. [PMID: 29380174 DOI: 10.1007/s10620-018-4942-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
6 Nakamura S, Imaeda H, Nishikawa H, Iimuro M, Matsuura M, Oka H, Oku J, Miyazaki T, Honda H, Watanabe K, Nakase H, Andoh A. Usefulness of fecal calprotectin by monoclonal antibody testing in adult Japanese with inflammatory bowel diseases: a prospective multicenter study. Intest Res 2018;16:554-62. [PMID: 30301337 DOI: 10.5217/ir.2018.00027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
7 Ji CC, Takano S. Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease. Intest Res 2017;15:182-6. [PMID: 28522947 DOI: 10.5217/ir.2017.15.2.182] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
8 Shimizu T, Masuo Y, Takahashi S, Nakamichi N, Kato Y. Organic cation transporter Octn1-mediated uptake of food-derived antioxidant ergothioneine into infiltrating macrophages during intestinal inflammation in mice. Drug Metab Pharmacokinet 2015;30:231-9. [PMID: 26003890 DOI: 10.1016/j.dmpk.2015.02.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
9 Lui RNS, Ng SC. The Same Intestinal Inflammatory Disease despite Different Genetic Risk Factors in the East and West? Inflamm Intest Dis 2016;1:78-84. [PMID: 29922661 DOI: 10.1159/000446625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Suzuki Y, Iida M, Ito H, Tachikawa N, Hibi T. Investigation of a High-Dose pH-Dependent-Release Mesalazine on the Induction of Remission in Active Crohn's Disease. Drugs R D 2016;16:35-43. [PMID: 26883035 DOI: 10.1007/s40268-015-0113-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
11 Makharia GK. Quality of care in Crohn's disease. World J Gastrointest Pathophysiol 2014; 5(4): 462-466 [PMID: 25400990 DOI: 10.4291/wjgp.v5.i4.462] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
12 Imaeda H, Bamba S, Takahashi K, Fujimoto T, Ban H, Tsujikawa T, Sasaki M, Fujiyama Y, Andoh A. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment. J Gastroenterol. 2014;49:674-682. [PMID: 23666424 DOI: 10.1007/s00535-013-0829-7] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 8.2] [Reference Citation Analysis]
13 Miyazaki C, Katsumasa N, Huang KC, Liu YF. Evaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an insurance database in Japan. PLoS One 2021;16:e0254807. [PMID: 34280242 DOI: 10.1371/journal.pone.0254807] [Reference Citation Analysis]
14 Motoya S, Watanabe M, Wallace K, Lazar A, Nishimura Y, Ozawa M, Thakkar R, Robinson AM, Singh RSP, Mostafa NM, Suzuki Y, Hibi T. Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy. Inflamm Intest Dis 2018;2:228-35. [PMID: 30221150 DOI: 10.1159/000486786] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
15 Elia J, Kane S. Adult Inflammatory Bowel Disease, Physical Rehabilitation, and Structured Exercise. Inflamm Bowel Dis. 2018;24:2543-2549. [PMID: 29850914 DOI: 10.1093/ibd/izy199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
16 Hu C, Lv L, Liu D, Huo J. Treatment of Crohn's disease complicated with myelodysplastic syndrome via allogeneic hematopoietic stem cell transplantation: case report and literature review. Clin J Gastroenterol 2014;7:299-304. [PMID: 25132866 DOI: 10.1007/s12328-014-0496-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
17 Fujimoto K, Fujishiro M, Kato M, Higuchi K, Iwakiri R, Sakamoto C, Uchiyama S, Kashiwagi A, Ogawa H, Murakami K, Mine T, Yoshino J, Kinoshita Y, Ichinose M, Matsui T;  Japan Gastroenterological Endoscopy Society. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Dig Endosc. 2014;26:1-14. [PMID: 24215155 DOI: 10.1111/den.12183] [Cited by in Crossref: 195] [Cited by in F6Publishing: 174] [Article Influence: 21.7] [Reference Citation Analysis]
18 Saigusa N, Yokoyama T, Shinozaki M, Miyahara R, Konishi T, Nakamura T, Yokoyama Y. Anorectal fistula is an early manifestation of Crohn's disease that occurs before bowel lesions advance: a study of 11 cases. Clin J Gastroenterol 2013;6:309-14. [PMID: 26181735 DOI: 10.1007/s12328-013-0404-z] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
19 Andoh A, Kobayashi T, Kuzuoka H, Tsujikawa T, Suzuki Y, Hirai F, Matsui T, Nakamura S, Matsumoto T, Fujiyama Y. Characterization of gut microbiota profiles by disease activity in patients with Crohn's disease using data mining analysis of terminal restriction fragment length polymorphisms. Biomed Rep 2014;2:370-3. [PMID: 24748976 DOI: 10.3892/br.2014.252] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
20 Saigusa N, Saigusa JI, Shinozaki M, Yokoyama T, Yokoi Y, Takami H, Miyahara R, Yokoyama Y. A series of seton techniques involving "top-down therapy" for patients with Crohn's disease who initially presented with perianal fistulas. J Anus Rectum Colon 2018;2:122-9. [PMID: 31559354 DOI: 10.23922/jarc.2017-044] [Reference Citation Analysis]
21 Ito Z, Uchiyama K, Odahara S, Takami S, Saito K, Kobayashi H, Koido S, Kubota T, Ohkusa T, Saruta M. Fatty Acids as Useful Serological Markers for Crohn's Disease. Dig Dis 2018;36:209-17. [PMID: 29275413 DOI: 10.1159/000485096] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
22 DeWitt T, Hegazi R. Nutrition in pelvic radiation disease and inflammatory bowel disease: similarities and differences. Biomed Res Int 2014;2014:716579. [PMID: 24982906 DOI: 10.1155/2014/716579] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
23 Inoue H, Shiwaku H, Iwakiri K, Onimaru M, Kobayashi Y, Minami H, Sato H, Kitano S, Iwakiri R, Omura N, Murakami K, Fukami N, Fujimoto K, Tajiri H. Clinical practice guidelines for peroral endoscopic myotomy. Dig Endosc. 2018;30:563-579. [PMID: 30022514 DOI: 10.1111/den.13239] [Cited by in Crossref: 60] [Cited by in F6Publishing: 38] [Article Influence: 15.0] [Reference Citation Analysis]
24 Wei SC, Chang TA, Chao TH, Chen JS, Chou JW, Chou YH, Chuang CH, Hsu WH, Huang TY, Hsu TC, Lin CC, Lin HH, Lin JK, Lin WC, Ni YH, Shieh MJ, Shih IL, Shun CT, Tsang YM, Wang CY, Wang HY, Weng MT, Wu DC, Wu WC, Yen HH, Wong JM. Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. Intest Res 2017;15:285-310. [PMID: 28670226 DOI: 10.5217/ir.2017.15.3.285] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
25 Kimura K, Takayanagi R, Yokoyama H, Yamada Y. Effects of tumor necrosis factor α-857C/T polymorphism on the expression of tumor necrosis factor α. APMIS 2016;124:669-74. [DOI: 10.1111/apm.12559] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
26 Rocha A, Bessa I, Lago P, Santos MD, Leite J, Castro-Poças F. Preoperative Enteral Nutrition and Surgical Outcomes in Adults with Crohn's Disease: A Systematic Review. GE Port J Gastroenterol 2019;26:184-95. [PMID: 31192287 DOI: 10.1159/000494674] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
27 Ishige T, Tomomasa T, Tajiri H, Yoden A; Japanese Study Group for Pediatric Crohn's Disease. Japanese physicians' attitudes towards enteral nutrition treatment for pediatric patients with Crohn's disease: a questionnaire survey. Intest Res 2017;15:345-51. [PMID: 28670231 DOI: 10.5217/ir.2017.15.3.345] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
28 Sugita N, Watanabe K, Kamata N, Yukawa T, Otani K, Hosomi S, Nagami Y, Tanaka F, Taira K, Yamagami H, Tanigawa T, Shiba M, Watanabe T, Tominaga K, Kabata D, Shintani A, Arakawa T, Fujiwara Y. Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease: Adalimumab with elemental diet in Crohn. Journal of Gastroenterology and Hepatology 2018;33:631-7. [DOI: 10.1111/jgh.13969] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
29 Nulsen B, Sands BE, Shah BJ, Ungaro RC. Practices, attitudes, and knowledge about Crohn’s disease and smoking cessation among gastroenterologists: . European Journal of Gastroenterology & Hepatology 2018;30:155-60. [DOI: 10.1097/meg.0000000000001010] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
30 Shaikhkhalil AK, Crandall W. Enteral Nutrition for Pediatric Crohn's Disease: An Underutilized Therapy. Nutr Clin Pract 2018;33:493-509. [PMID: 29446858 DOI: 10.1002/ncp.10011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Genualdi M, Lebovics E, Frishman AWH. Novel Oral Anticoagulants in the Peri-Endoscopic Period. Cardiol Rev 2017;25:223-9. [PMID: 28604566 DOI: 10.1097/CRD.0000000000000149] [Reference Citation Analysis]
32 He Y, Mao R, Chen F, Xu PP, Chen BL, Wu Y, Qiu Y, Zhang SH, Feng R, Zeng ZR, Ben-Horin S, Chen MH. Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label study. Therap Adv Gastroenterol 2017;10:397-406. [PMID: 28507598 DOI: 10.1177/1756283X17698910] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
33 Park JJ, Yang SK, Ye BD, Kim JW, Park DI, Yoon H, Im JP, Lee KM, Yoon SN, Lee H; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. [Second Korean Guidelines for the Management of Crohn's Disease]. Korean J Gastroenterol 2017;69:29-54. [PMID: 28135790 DOI: 10.4166/kjg.2017.69.1.29] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
34 Di Caro S, Fragkos KC, Keetarut K, Koo HF, Sebepos-Rogers G, Saravanapavan H, Barragry J, Rogers J, Mehta SJ, Rahman F. Enteral Nutrition in Adult Crohn's Disease: Toward a Paradigm Shift. Nutrients 2019;11:E2222. [PMID: 31540038 DOI: 10.3390/nu11092222] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
35 Häuser W, Moser G, Klose P, Mikocka-Walus A. Psychosocial issues in evidence-based guidelines on inflammatory bowel diseases: A review. World J Gastroenterol 2014; 20(13): 3663-3671 [PMID: 24707152 DOI: 10.3748/wjg.v20.i13.3663] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
36 Sagami S, Ueno Y, Tanaka S, Fujita A, Hayashi R, Oka S, Hyogo H, Chayama K. Significance of non-alcoholic fatty liver disease in Crohn's disease: A retrospective cohort study: NAFLD significance in Crohn's disease. Hepatol Res 2017;47:872-81. [DOI: 10.1111/hepr.12828] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
37 Cao X, Cao L, Zhang W, Lu R, Bian JS, Nie X. Therapeutic potential of sulfur-containing natural products in inflammatory diseases. Pharmacol Ther 2020;216:107687. [PMID: 32966837 DOI: 10.1016/j.pharmthera.2020.107687] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Suzuki T, Mizoshita T, Sugiyama T, Hirata Y, Kimura Y, Suzuki Y, Yamada T, Tsukamoto H, Mizushima T, Sugimura N, Katano T, Tanida S, Kataoka H, Sasaki M. Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment. Case Rep Gastroenterol 2019;13:37-49. [PMID: 31182942 DOI: 10.1159/000496453] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
39 Esaki M, Umeno J, Kitazono T, Matsumoto T. Clinicopathologic features of chronic nonspecific multiple ulcers of the small intestine. Clin J Gastroenterol 2015;8:57-62. [PMID: 25788296 DOI: 10.1007/s12328-015-0559-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
40 Ueda T, Inoue T, Nakamoto T, Nishigori N, Kuge H, Sasaki Y, Fujii H, Koyama F. Anorectal Cancer in Crohn's Disease Has a Poor Prognosis Due to its Advanced Stage and Aggressive Histological Features: a Systematic Literature Review of Japanese Patients. J Gastrointest Cancer 2020;51:1-9. [PMID: 30474795 DOI: 10.1007/s12029-018-0180-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
41 Fujiya M, Sakatani A, Dokoshi T, Tanaka K, Ando K, Ueno N, Gotoh T, Kashima S, Tominaga M, Inaba Y. A Bamboo Joint-Like Appearance is a Characteristic Finding in the Upper Gastrointestinal Tract of Crohn’s Disease Patients: A Case-Control Study. Medicine (Baltimore). 2015;94:e1500. [PMID: 26376393 DOI: 10.1097/md.0000000000001500] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
42 Horio Y, Uchino M, Hori K, Kusunoki K, Minagawa T, Kuwahara R, Kataoka K, Beppu N, Ikeda M, Ikeuchi H. Clinical Features and Therapeutic Outcomes of Post-colectomy Enteritis with Ulcerative Colitis. J Anus Rectum Colon 2021;5:405-13. [PMID: 34746505 DOI: 10.23922/jarc.2021-031] [Reference Citation Analysis]
43 Shinagawa T, Hata K, Ikeuchi H, Fukushima K, Futami K, Sugita A, Uchino M, Watanabe K, Higashi D, Kimura H, Araki T, Mizushima T, Itabashi M, Ueda T, Koganei K, Oba K, Ishihara S, Suzuki Y. Rate of Reoperation Decreased Significantly After Year 2002 in Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2020;18:898-907.e5. [PMID: 31336198 DOI: 10.1016/j.cgh.2019.07.025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
44 Goldowsky A, Sen R, Hoffman G, Feuerstein JD. Is there a standardized practice for the development of international ulcerative colitis and Crohn's disease treatment guidelines? Gastroenterol Rep (Oxf) 2021;9:408-17. [PMID: 34733526 DOI: 10.1093/gastro/goab009] [Reference Citation Analysis]
45 Lee WS, Azmi N, Ng RT, Ong SY, Ponnampalavanar SS, Mahadeva S, Hilmi I. Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy. Intest Res 2017;15:524-8. [PMID: 29142521 DOI: 10.5217/ir.2017.15.4.524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
46 Xu Y, Qiao YQ, Li HY, Zhou M, Cai CW, Shen J, Ran ZH. NUDT15 genotyping during azathioprine treatment in patients with inflammatory bowel disease: implications for a dose-optimization strategy. Gastroenterol Rep (Oxf) 2020;8:437-44. [PMID: 33442476 DOI: 10.1093/gastro/goaa021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
47 Watanabe Y, Miyoshi N, Fujino S, Takahashi H, Haraguchi N, Hata T, Matsuda C, Yamamoto H, Doki Y, Mori M, Mizushima T. Cumulative Inflammation Could Be a Risk Factor for Intestinal Failure in Crohn's Disease. Dig Dis Sci. 2019;64:2280-2285. [PMID: 30806860 DOI: 10.1007/s10620-019-05553-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
48 Chang CW, Wei SC, Chou JW, Hsu TC, Chuang CH, Lin CP, Hsu WH, Yen HH, Lin JK, Fang YJ, Wang HY, Lin HH, Wu DC, Ni YH, Wang CY, Wong JM. Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study. Intest Res 2014;12:287-92. [PMID: 25374494 DOI: 10.5217/ir.2014.12.4.287] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
49 Mitsuyama K, Niwa M, Masuda J, Yamasaki H, Kuwaki K, Takedatsu H, Kobayashi T, Kinjo F, Kishimoto K, Matsui T, Hirai F, Makiyama K, Ohba K, Abe H, Tsubouchi H, Fujita H, Maekawa R, Yoshida H, Sata M; The Kyushu ACP Study Group. Possible diagnostic role of antibodies to Crohn’s disease peptide (ACP): results of a multicenter study in a Japanese cohort. J Gastroenterol 2014;49:683-91. [DOI: 10.1007/s00535-013-0916-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
50 Kim JW. Results of the first survey for the current status of inflammatory bowel disease management in Asian countries. Intest Res 2016;14:199-201. [PMID: 27433140 DOI: 10.5217/ir.2016.14.3.199] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
51 de Groof EJ, Cabral VN, Buskens CJ, Morton DG, Hahnloser D, Bemelman WA; research committee of the European Society of Coloproctology. Systematic review of evidence and consensus on perianal fistula: an analysis of national and international guidelines. Colorectal Dis. 2016;18:O119-O134. [PMID: 26847796 DOI: 10.1111/codi.13286] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
52 Park JJ, Yang SK, Ye BD, Kim JW, Park DI, Yoon H, Im JP, Lee KM, Yoon SN, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of Crohn's disease. Intest Res 2017;15:38-67. [PMID: 28239314 DOI: 10.5217/ir.2017.15.1.38] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
53 Fukata N, Okazaki K, Omiya M, Matsushita M, Watanabe M; Members of the Ministry of Health and Welfare of Japan’s Inflammatory Bowel Diseases Study Group. Hematologic malignancies in the Japanese patients with inflammatory bowel disease. J Gastroenterol 2014;49:1299-306. [PMID: 23955181 DOI: 10.1007/s00535-013-0873-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
54 Yokoyama K, Yamazaki K, Katafuchi M, Ferchichi S. A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab. Adv Ther 2016;33:1947-63. [PMID: 27664107 DOI: 10.1007/s12325-016-0406-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
55 Takaoka A, Sasaki M, Kurihara M, Iwakawa H, Inoue M, Bamba S, Ban H, Andoh A, Miyazaki Y. Comparison of energy metabolism and nutritional status of hospitalized patients with Crohn's disease and those with ulcerative colitis. J Clin Biochem Nutr 2015;56:208-14. [PMID: 26060351 DOI: 10.3164/jcbn.14-95] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
56 Imaeda H, Takahashi K, Fujimoto T, Bamba S, Tsujikawa T, Sasaki M, Fujiyama Y, Andoh A. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease. J Gastroenterol. 2014;49:100-109. [PMID: 23575576 DOI: 10.1007/s00535-013-0803-4] [Cited by in Crossref: 68] [Cited by in F6Publishing: 56] [Article Influence: 7.6] [Reference Citation Analysis]
57 Mizoshita T, Tanida S, Tsukamoto H, Ozeki K, Katano T, Nishiwaki H, Ebi M, Mori Y, Kubota E, Kataoka H, Kamiya T, Joh T. Adalimumab Treatment in Biologically Naïve Crohn's Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement. Gastroenterol Res Pract 2014;2014:687257. [PMID: 24829572 DOI: 10.1155/2014/687257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
58 Wu J, Gao Y, Yang C, Yang X, Li X, Xiao S. Low-dose azathioprine is effective in maintaining remission among Chinese patients with Crohn's disease. J Transl Med 2013;11:235. [PMID: 24070341 DOI: 10.1186/1479-5876-11-235] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
59 Kobayashi T, Hisamatsu T, Suzuki Y, Ogata H, Andoh A, Araki T, Hokari R, Iijima H, Ikeuchi H, Ishiguro Y, Kato S, Kunisaki R, Matsumoto T, Motoya S, Nagahori M, Nakamura S, Nakase H, Tsujikawa T, Sasaki M, Yokoyama K, Yoshimura N, Watanabe K, Katafuchi M, Watanabe M, Hibi T. Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries. Intest Res 2018;16:168-77. [PMID: 29743830 DOI: 10.5217/ir.2018.16.2.168] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
60 Shimizu Y, Takaku H, Paku S, Azuma K, Suzuki T, Kashimura H, Ohtani H, Ohkochi N. A patient with colitis-associated cancer who developed clinically manifest Crohn's disease only after surgery. Surg Case Rep 2020;6:68. [PMID: 32277311 DOI: 10.1186/s40792-020-0779-2] [Reference Citation Analysis]
61 Araki T, Okita Y, Kondo S, Hiro J, Toiyama Y, Inoue M, Ohi M, Inoue Y, Uchida K, Mohri Y, Kusunoki M. Risk factors for recurrence of Crohn's disease requiring surgery in patients receiving post-operative anti-tumor necrosis factor maintenance therapy. J Anus Rectum Colon 2017;1:15-21. [PMID: 31583295 DOI: 10.23922/jarc.2016-004] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
62 Otagiri S, Ohnishi S, Miura A, Hayashi H, Kumagai I, Ito YM, Katsurada T, Nakamura S, Okamoto R, Yamahara K, Cho KY, Isoe T, Sato N, Sakamoto N. Evaluation of amnion-derived mesenchymal stem cells for treatment-resistant moderate Crohn's disease: study protocol for a phase I/II, dual-centre, open-label, uncontrolled, dose-response trial. BMJ Open Gastroenterol 2018;5:e000206. [PMID: 29915666 DOI: 10.1136/bmjgast-2018-000206] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
63 Sultan KS, Berkowitz JC, Khan S. Combination therapy for inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2017; 8(2): 103-113 [PMID: 28533919 DOI: 10.4292/wjgpt.v8.i2.103] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
64 Kobayashi T, Hishida A, Tanaka H, Nuki Y, Bamba S, Yamada A, Fujii T, Shinzaki S, Yokoyama Y, Yoshida A, Ozeki K, Ashizuka S, Kamata N, Nanjo S, Kakimoto K, Nakamura M, Matsui A, Yamauchi R, Takahashi S, Tomizawa T, Yoshino T, Hibi T. Real-world Experience of Anti–tumor Necrosis Factor Therapy for Internal Fistulas in Crohnʼs Disease: A Retrospective Multicenter Cohort Study. Inflammatory Bowel Diseases 2017;23:2245-51. [DOI: 10.1097/mib.0000000000001276] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
65 Bennett AL, Munkholm P, Andrews JM. Tools for primary care management of inflammatory bowel disease: Do they exist? World J Gastroenterol 2015; 21(15): 4457-4465 [PMID: 25914455 DOI: 10.3748/wjg.v21.i15.4457] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
66 Yasukawa S, Matsui T, Yano Y, Sato Y, Takada Y, Kishi M, Ono Y, Takatsu N, Nagahama T, Hisabe T, Hirai F, Yao K, Ueki T, Higashi D, Futami K, Sou S, Sakurai T, Yao T, Tanabe H, Iwashita A, Washio M. Crohn's disease-specific mortality: a 30-year cohort study at a tertiary referral center in Japan. J Gastroenterol 2019;54:42-52. [PMID: 29948302 DOI: 10.1007/s00535-018-1482-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
67 Matsumoto H, Ohfuji S, Watanabe K, Yamagami H, Fukushima W, Maeda K, Kamata N, Sogawa M, Shiba M, Tanigawa T, Tominaga K, Watanabe T, Fujiwara Y, Hirota Y, Arakawa T. Booster influenza vaccination does not improve immune response in adult inflammatory bowel disease patients treated with immunosuppressives: a randomized controlled trial. J Gastroenterol 2015;50:876-86. [PMID: 25672513 DOI: 10.1007/s00535-015-1042-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
68 Schwartzberg DM, Brandstetter S, Grucela AL. Crohn's Disease of the Esophagus, Duodenum, and Stomach. Clin Colon Rectal Surg 2019;32:231-42. [PMID: 31275069 DOI: 10.1055/s-0039-1683850] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
69 Urabe S, Isomoto H, Ishida T, Maeda K, Inamine T, Kondo S, Higuchi N, Sato K, Uehara R, Yajima H, Machida H, Chen CC, Fukuda Y, Takeshima F, Nakao K, Tsukamoto K. Genetic Polymorphisms of IL-17F and TRAF3IP2 Could Be Predictive Factors of the Long-Term Effect of Infliximab against Crohn's Disease. Biomed Res Int 2015;2015:416838. [PMID: 26558270 DOI: 10.1155/2015/416838] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
70 Uchiyama K, Kishi H, Komatsu W, Nagao M, Ohhira S, Kobashi G. Lipid and Bile Acid Dysmetabolism in Crohn's Disease. J Immunol Res 2018;2018:7270486. [PMID: 30402511 DOI: 10.1155/2018/7270486] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
71 Yazısız V. Similarities and differences between Behçet's disease and Crohn's disease. World J Gastrointest Pathophysiol 2014; 5(3): 228-238 [PMID: 25133025 DOI: 10.4291/wjgp.v5.i3.228] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
72 Sato Y, Matsui T, Yano Y, Tsurumi K, Okado Y, Matsushima Y, Koga A, Takahashi H, Ninomiya K, Ono Y, Takatsu N, Beppu T, Nagahama T, Hisabe T, Takaki Y, Hirai F, Yao K, Higashi D, Futami K, Washio M. Long-term course of Crohn's disease in Japan: Incidence of complications, cumulative rate of initial surgery, and risk factors at diagnosis for initial surgery. J Gastroenterol Hepatol. 2015;30:1713-1719. [PMID: 26094852 DOI: 10.1111/jgh.13013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
73 Qian X, Wang T, Shen J, Ran Z. Low dose of azathioprine is effective to induce and maintain remission in active Crohn disease: A prospective observational study. Medicine (Baltimore) 2018;97:e11814. [PMID: 30142769 DOI: 10.1097/MD.0000000000011814] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
74 Yokoyama T, Ohta A, Motoya S, Takazoe M, Yajima T, Date M, Nii M, Nagy P, Suzuki Y, Hibi T. Efficacy and Safety of Oral Budesonide in Patients with Active Crohn's Disease in Japan: A Multicenter, Double-Blind, Randomized, Parallel-Group Phase 3 Study. Inflamm Intest Dis. 2018;2:154-162. [PMID: 29922676 DOI: 10.1159/000484047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
75 Nam K, Jung WB, Lee SB, Soh JS, Yang SS, Jung SW. Predictors of reoperation for perianal fistula in Crohn's disease. J Dig Dis 2021;22:334-41. [PMID: 33949127 DOI: 10.1111/1751-2980.12996] [Reference Citation Analysis]